Neurotrophic Keratitis Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $5.1 billion in 2024 to $5.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.39 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

The increasing prevalence of eye diseases is expected to drive the growth of the neurotrophic keratitis treatment market in the coming years. Eye diseases encompass a wide range of conditions that impact the structure and function of the eyes. Neurotrophic keratitis is a condition that can help improve corneal sensation, promote healing, prevent infection, and alleviate pain. For example, in March 2022, Eye Care One, a U.S.-based eyecare career development platform, reported that an estimated 35 million people in the U.S. were affected by dry eye disease (DED) in 2022, with the prevalence expected to rise annually. Furthermore, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S. federal agency under the Department of Health and Human Services, stated that over 3.4 million Americans aged 40 and older are blind or visually impaired, a number expected to double by 2030. As a result, the growing prevalence of eye diseases is driving the expansion of the neurotrophic keratitis treatment market.

The growing investments in healthcare, particularly in eye care, are expected to drive the growth of the neurotrophic keratitis treatment market in the future. Investments in healthcare, including eye care, refer to the financial resources allocated to enhance the development, improvement, and accessibility of medical services and treatments, with a specific focus on vision-related health issues. These investments can play a pivotal role in advancing the treatment of neurotrophic keratitis, leading to breakthroughs in therapies, drug development, and ultimately improving patient outcomes and quality of life for those affected by the condition. For example, in March 2022, the Department of Health and Aged Care, an Australian government department overseeing health research and funding, reported that government investment in health systems amounted to $132 billion in 2022-23, with projections to increase to $140 billion by 2025-26, totaling $537 billion over the next four years. Therefore, the rise in healthcare investments, including in eye care, is contributing to the growth of the neurotrophic keratitis treatment market.

Major companies operating in the neurotrophic keratitis treatment market are focusing on developing innovative drugs to strengthen their market presence. Drug development is crucial in the treatment of neurotrophic keratitis, as current therapies are limited, and there is a pressing need for more effective treatments to halt disease progression. For example, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug BRM424, aimed at treating neurotrophic keratitis (NK). BRM424 is a recombinant human nerve growth factor that works by stimulating the proliferation and differentiation of corneal limbal stem cells, which helps regenerate and restore the cornea's health in patients with neurotrophic keratitis. This innovative approach reflects the ongoing efforts to address the unmet medical needs in this field.

In July 2022, Regenerx Biopharmaceuticals Inc., a US-based clinical-stage drug development company, along with its joint venture and licensee partner, HLB Therapeutics Co. Ltd., a biotechnology company based in South Korea, entered into a letter of intent with a global ophthalmology contract research organization (CRO). This collaboration is focused on conducting Phase III clinical trials in the US and Europe for the treatment of neurotrophic keratitis (NK). RGN-259, a sterile and preservative-free eye drop formulation containing thymosin beta 4, a naturally occurring peptide that facilitates tissue repair and healing, is the subject of evaluation. The Phase III clinical trial will assess the efficacy and safety of RGN-259 ophthalmic solution in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathies.clinical-stage drug development company.

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neurotrophic keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Neurotrophic keratitis treatment is a method aimed at addressing a rare eye condition resulting from damage to the trigeminal nerve, leading to reduced corneal sensation and potential corneal harm. The objective of this treatment is to safeguard the cornea, facilitate recovery, alleviate symptoms, and prevent further damage. aimed at addressing a rare.

The main approaches of neurotrophic keratitis treatment are employed in neurotrophic keratitis treatment, including topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, among others. Topical antibiotics are antimicrobial drugs administered directly to the skin or mucous membranes. They can be administered through various routes, such as oral, topical, and others, catering to stages I, II, and III of neurotropic keratitis. These treatments are utilized by different end-users, including hospitals, homecare, specialty clinics, among others.

The neurotrophic keratitis treatment market research report is one of a series of new reports that provides neurotrophic keratitis treatment market statistics, including neurotrophic keratitis treatment industry global market size, regional shares, competitors with a neurotrophic keratitis treatment market share, detailed neurotrophic keratitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurotrophic keratitis treatment industry. This neurotrophic keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.